Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial basliginda one cikan gelisme: Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.